Product Information
FOCALIN XR 30 MG CAPSULE is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $4.7537 per EA under NDC 00078043305. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on May 26, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the dexmethylphenidate hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078043305
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
DEXMETHYLPHENIDATE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA021802FDA Approved
5/26/2005
TE Code
AB
On Market Since
5/31/2005
Pharmacological Classes
Price Statistics
The NADAC for FOCALIN XR 30 MG CAPSULE has been published 665 times since Nov 28, 2013, and over the history we have for it it has declined 26.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.7537 per EA |
|---|---|
| All-time high | $13.0729 (Oct 11, 2023) |
| All-time low | $4.7225 (Sep 18, 2024) |
| 52-week high | $4.7684 |
| 52-week low | $4.7317 |
| Median price | $10.9929 |
| Average price | $9.7526 |
| Largest weekly change | -63.8% (Apr 3, 2024) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 63% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of FOCALIN XR 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for FOCALIN XR 30 MG CAPSULE, manufactured by Novartis Pharmaceuticals Corporation, is $4.7537 per EA (NDC 00078043305), effective Aug 19, 2026.
How has the price of FOCALIN XR 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for FOCALIN XR 30 MG CAPSULE has declined 26.2%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for FOCALIN XR 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for FOCALIN XR 30 MG CAPSULE has ranged from a low of $4.7225 (Sep 18, 2024) to a high of $13.0729 (Oct 11, 2023), with a median of $10.9929 per EA.
Are there cheaper alternatives to FOCALIN XR 30 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DEXMETHYLPHENIDATE ER 30 MG CP, is $1.7632 per EA — about 63% below FOCALIN XR 30 MG CAPSULE.
Who manufactures FOCALIN XR 30 MG CAPSULE?
FOCALIN XR 30 MG CAPSULE (NDC 00078043305) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.